C. Fichtenbaum

G. Bloomfield, C. Fichtenbaum, K. Ruxrungtham, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.

C. Fichtenbaum, J. Currier, J. Feinberg, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Steady‐State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid‐Lowering Agent Rosuvastatin

C. Fichtenbaum, P. Desai, L. Sallans, 2012, Journal of clinical pharmacology.

Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy:

C. Fichtenbaum, E. Acosta, D. Kitch, 2009 .

Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

C. Fichtenbaum, S. Evans, J. Aberg, 2010, Journal of clinical lipidology.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Mycobacterium bovis Bacille-Calmette-Guérin Infection Aggravates Atherosclerosis

C. Fichtenbaum, G. Deepe, D. Hui, 2020, Frontiers in Immunology.

Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.

M. Lyons, C. Fichtenbaum, K. Hart, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of Bordetella pertussis Infection in Adolescents and Adults

C. Fichtenbaum, J. Ying, 2010 .

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Genotypic and phenotypic characterization of Cryptosporidium parvum isolates from people with AIDS.

C. Fichtenbaum, S. Tzipori, J. Griffiths, 1998, The Journal of infectious diseases.

Metabolic abnormalities associated with HIV infection and antiretroviral therapy

C. Fichtenbaum, 2009, Current infectious disease reports.

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

W. K. Henry, C. Fichtenbaum, S. Evans, 2005, AIDS research and human retroviruses.

Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection

C. Fichtenbaum, 2011, Current infectious disease reports.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity

R. Haubrich, K. Tashima, V. Johnson, 2015, HIV clinical trials.

Does Antiretroviral Therapy Increase or Decrease the Risk of Cardiovascular Disease?

C. Fichtenbaum, 2010, Current HIV/AIDS reports.

Review of duodenal diverticula.

C. Fichtenbaum, H. Taubin, S. Afridi, 1991, The American journal of gastroenterology.

Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.

C. Fichtenbaum, D. Hui, Tara M. Riddle, 2003, Journal of acquired immune deficiency syndromes.

Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.

C. Fichtenbaum, D. Clifford, P. Tebas, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV

G. Bloomfield, C. Fichtenbaum, P. Douglas, 2022, Journal of acquired immune deficiency syndromes.

Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART

C. Fichtenbaum, A. Somasunderam, D. Asmuth, 2019, Pathogens & immunity.

The Prevalence and Signiﬁcance of Occult Hepatitis B Virus in a Prospective Cohort of HIV-Infected Patients

C. M. Martin, N. Shire, C. Fichtenbaum, 2018 .

The Prevalence and Significance of Occult Hepatitis B Virus in a Prospective Cohort of HIV-Infected Patients

C. M. Martin, N. Shire, C. Fichtenbaum, 2007, Journal of acquired immune deficiency syndromes.

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy

C. Fichtenbaum, G. Guaraldi, J. Stein, 2010, AIDS.

A truvada hypersensitivity reaction simulating abacavir hypersensitivity.

C. Fichtenbaum, Marie A. de Perio, P. Frame, 2007, AIDS.

Monocyte activation in persons living with HIV and tuberculosis coinfection.

C. Fichtenbaum, C. Longenecker, C. Kityo, 2020, AIDS.

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1A Randomized, Controlled Equivalence TrialNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

D. Kuritzkes, C. Fichtenbaum, D. Haas, 2014 .

COVID-19 Vaccination Rates in a Global HIV Cohort.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2021, The Journal of infectious diseases.

Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.

C. Fichtenbaum, C. Chougnet, P. Velilla, 2008, AIDS research and human retroviruses.

Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma

C. Fichtenbaum, D. Clifford, W. Powderly, 1995, Journal of clinical microbiology.

Eosinophilic granuloma of the lung presenting as a solitary pulmonary nodule.

C. Fichtenbaum, G. Kleinman, R. Haddad, 1990, Thorax.

Evolocumab in HIV-Infected Patients With Dyslipidemia

Paul D. Thompson, S. Trottier, C. Fichtenbaum, 2020, Journal of the American College of Cardiology.

Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2021, Journal of acquired immune deficiency syndromes.

Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir

C. Fichtenbaum, B. Taiwo, T. Brown, 2016, AIDS.

Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study.

C. Fichtenbaum, W. Powderly, K. Woeltje, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers

C. Fichtenbaum, A. Zolopa, J. Aberg, 2005, Clinical pharmacology and therapeutics.

The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction

C. Fichtenbaum, T. Sterling, R. Kryscio, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.

Matthew A. Meier, C. Fichtenbaum, Jun Ying, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2

S. Schaffert, P. Khatri, Rhiju Das, 2022, Nature Medicine.

Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

C. Fichtenbaum, P. Sax, S. Gianella, 2018, Journal of acquired immune deficiency syndromes.

Effects of HIV infection and antiretroviral therapy on the heart and vasculature.

C. Fichtenbaum, S. Lipshultz, S. Fisher, 2008, Circulation.

A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy

C. Fichtenbaum, J. Brenchley, D. Kitch, 2021, Open forum infectious diseases.

Schistosomiasis, an Unusual Cause of Variceal Bleeding in the United States

C. Fichtenbaum, R. Giannella, Vivek Batra, 2013 .

A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

C. Fichtenbaum, J. Vazquez, A. Reboli, 2008, Journal of acquired immune deficiency syndromes.

Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.

R. Parker, C. Fichtenbaum, K. Squires, 2008, Journal of clinical lipidology.

Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection

C. Fichtenbaum, W. Powderly, B. Zingman, 2000, AIDS.

Antiretrovirals and cardiovascular disease: is HAART bad for your heart?

C. Fichtenbaum, 2003, AIDS clinical care.

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors

R. Haubrich, K. Tashima, V. Johnson, 2015, Annals of Internal Medicine.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

C. Fichtenbaum, H. Stellbrink, M. Saag, 2016, AIDS.

Refractory mucosal candidiasis in patients with human immunodeficiency virus infection.

C. Fichtenbaum, W. Powderly, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD40 Ligand Dysregulation in HIV Infection: HIV Glycoprotein 120 Inhibits Signaling Cascades Upstream of CD40 Ligand Transcription1

C. Fichtenbaum, J. Lifson, C. Chougnet, 2004, The Journal of Immunology.

TranscriptionCascades Upstream of CD40 Ligand HIV Glycoprotein 120 Inhibits Signaling CD40 Ligand Dysregulation in HIV Infection:

C. Fichtenbaum, J. Lifson, C. Chougnet, 2004 .

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.

W. K. Henry, K. Tashima, C. Fichtenbaum, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087

C. Fichtenbaum, S. Evans, J. Aberg, 2007, HIV clinical trials.

Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

Daniel L. Popkin, M. Lederman, C. Fichtenbaum, 2018, Vaccine.

Cryptosporidium parvum Infection of Human Intestinal Xenografts in SCID Mice Induces Production of Human Tumor Necrosis Factor Alpha and Interleukin-8

C. Fichtenbaum, S. Tzipori, P. Swanson, 1998, Infection and Immunity.

HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the Nucleus*

C. Fichtenbaum, D. Hui, L. Woollett, 2001, The Journal of Biological Chemistry.

In Vitro HIV Infection Impairs the Capacity of Myeloid Dendritic Cells to Induce Regulatory T Cells

C. Fichtenbaum, C. Chougnet, Maria E. Moreno-Fernandez, 2012, PloS one.

Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru

C. Fichtenbaum, T. Sterling, R. Kryscio, 2018, PloS one.

Osteomyelitis of the skull in early-acquired syphilis: evaluation by MR imaging and CT.

R. Narayan, C. Fichtenbaum, J. Leach, 2007, AJNR. American journal of neuroradiology.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

K. Tashima, C. Fichtenbaum, L. Smeaton, 2019, The Journal of infectious diseases.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy : 96-week Results of AIDS Clinical Trials Group A 5241 ( OPTIONS )

K. Tashima, C. Fichtenbaum, --Manuscript Draft, 2019 .

Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons.

C. Fichtenbaum, P. Walzer, R. Tanaka, 2002, The Journal of infectious diseases.

Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk

G. Bloomfield, C. Fichtenbaum, K. Ruxrungtham, 2022, AIDS.

Women have enhance d bone loss associated with phosphaturia and CD 4 R cell restoration during initial antiretroviral therapy

S. Cremers, C. Fichtenbaum, B. Taiwo, 2018 .

Entrustment and Mapping of Observable Practice Activities for Resident Assessment

Jonathan Tolentino, Justin D. Held, C. Fichtenbaum, 2014, Journal of General Internal Medicine.

Specialty training and specialization among physicians who treat HIV/AIDS in the United States

Neil S. Wenger, Martin F. Shapiro, Samuel A. Bozzette, 2007, Journal of General Internal Medicine.

Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.

C. Yiannoutsos, C. Fichtenbaum, M. Saag, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An Immunocompetent Patient With Primary Scedosporium Apiospermum Vertebral Osteomyelitis

Nicholas B. Levine, C. Fichtenbaum, J. Howington, 2002, Journal of spinal disorders & techniques.

In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus.

C. Fichtenbaum, W. Powderly, R. Swoboda, 2000, The Journal of infectious diseases.

Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.

C. Yiannoutsos, C. Fichtenbaum, D. Skiest, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection

C. Fichtenbaum, C. Benson, J. Griffiths, 2000, AIDS.

Frequency of Circulating Regulatory T Cells Increases during Chronic HIV Infection and Is Largely Controlled by Highly Active Antiretroviral Therapy

C. Fichtenbaum, C. Chougnet, E. King, 2011, PloS one.

A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.

C. Fichtenbaum, J. Sobel, W. Powderly, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B.

C. Fichtenbaum, V. Fraser, W. C. Dunagan, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ischemic cardiovascular disease in persons with human immunodeficiency virus infection.

R. Hornung, C. Fichtenbaum, M. H. David, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS.

C. Fichtenbaum, W. Powderly, D. Ritchie, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman.

C. Fichtenbaum, R. Zackin, J. Feinberg, 2001, AIDS.

Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome.

C. Fichtenbaum, L. Peterson, G. Weil, 1993, The American journal of medicine.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

C. Fichtenbaum, P. Sax, E. Acosta, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108

C. Fichtenbaum, J. Aberg, J. Gerber, 2006, AIDS.

Emerging reverse transcriptase inhibitors for HIV-1 infection

C. Fichtenbaum, M. A. Rai, Sam Pannek, 2018, Expert opinion on emerging drugs.

Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection.

C. Fichtenbaum, D. Clifford, W. Powderly, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

C. Fichtenbaum, P. Sax, E. Daar, 2013, The Journal of infectious diseases.

Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

Jeannie S. Huang, C. Fichtenbaum, S. Swindells, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV Infection

C. Fichtenbaum, J. Gerber, 2002, Clinical pharmacokinetics.

Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.

C. Fichtenbaum, M. Glesby, R. Bassett, 2005, The Journal of infectious diseases.

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

R. Parker, C. Fichtenbaum, K. Squires, 2008, Journal of the American College of Cardiology.

Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study

C. Fichtenbaum, J. Aberg, J. Gerber, 2005, Journal of acquired immune deficiency syndromes.

Acyclovir-Induced Respiratory Depression in an AIDS Patient With End-Stage Renal Disease on Continuous Ambulatory Peritoneal Dialysis

C. Fichtenbaum, W. Hester, Sandeep Bansil, 2004 .

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

David W. Haas, Todd T. Brown, Daniel R. Kuritzkes, 2014, Annals of internal medicine.

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047

C. Fichtenbaum, T. Blaschke, J. Aberg, 2002, AIDS.

Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone

M. Lederman, C. Fichtenbaum, D. Douek, 2018, The Journal of infectious diseases.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

J. Mascola, C. Fichtenbaum, D. Follmann, 2021, The New England journal of medicine.

Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system.

C. Fichtenbaum, D. Clifford, W. Powderly, 1995, The Journal of infectious diseases.

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.

Karen L. Price, J. Ramirez, D. Skovronsky, 2021, JAMA.

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals

Hulin Wu, Song Yu, Edward P Acosta, 2004, Journal of acquired immune deficiency syndromes.

Physician specialization and antiretroviral therapy for HIV

I. Wilson, P. Cleary, C. Fichtenbaum, 2003, Journal of General Internal Medicine.

Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186

C. Fichtenbaum, E. Acosta, D. Kitch, 2008, Journal of acquired immune deficiency syndromes.

Impaired response of memory Treg to high density lipoproteins is associated with intermediate/high cardiovascular disease risk in persons with HIV

C. Fichtenbaum, C. Chougnet, W. Davidson, 2023, Frontiers in Immunology.

Coronary Heart Disease Risk, Dyslipidemia, and Management in HIV-Infected Persons

C. Fichtenbaum, 2004, HIV clinical trials.

Elevated lactate levels in hospitalized persons with HIV infection.

C. Fichtenbaum, P. Tebas, W. Powderly, 2001, AIDS research and human retroviruses.

Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.

C. Fichtenbaum, J. Currier, J. Stein, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea

A. LaMarca, C. Fichtenbaum, D. Asmuth, 2017, HIV clinical trials.

Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments.

P. Sullivan, M. Lyons, C. Lindsell, 2011, Annals of emergency medicine.

The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice DOI 10.1194/jlr.M200129-JLR200

C. Fichtenbaum, D. Hui, C. Phan, 2002, Journal of Lipid Research.

A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences.

M. Lyons, C. Lindsell, C. Fichtenbaum, 2007, BMC health services research.

The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial

C. Fichtenbaum, J. Aberg, S. Grinspoon, 2022, Contemporary clinical trials.

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

C. Fichtenbaum, P. Douglas, J. Currier, 2021, Open forum infectious diseases.

A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences

M. Lyons, C. Lindsell, C. Fichtenbaum, 2007, BMC Health Services Research.

Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy–Treated Individuals

C. Fichtenbaum, K. Robertson, B. Taiwo, 2019, Journal of acquired immune deficiency syndromes.

Authors' Reply: Campylobacter spp. Bacteremia in AIDS Patients

C. Fichtenbaum, W. C. Dunagan, W. Powderly, 1996 .

Preliminary program evaluation of emergency department HIV prevention counseling.

M. Lyons, C. Lindsell, C. Fichtenbaum, 2011, Annals of emergency medicine.

Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening.

M. Lyons, C. Lindsell, C. Fichtenbaum, 2011, The American journal of emergency medicine.

Comparison of emergency department HIV testing data with visit or patient as the unit of analysis

M. Lyons, C. Lindsell, C. Fichtenbaum, 2009, Journal of medical screening.

Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis

C. Fichtenbaum, T. Sterling, R. Kryscio, 2017, Epidemiology and Infection.

Contributions to early HIV diagnosis among patients linked to care vary by testing venue

M. Lyons, C. Lindsell, C. Fichtenbaum, 2008, BMC public health.

Challenges in Managing Hospitalized HIV Infected Persons with Low Absolute CD4 and Preserved CD4 Percentage

C. Fichtenbaum, S. Bobula, 2012 .

Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV

C. Fichtenbaum, J. Currier, J. Aberg, 2023, eBioMedicine.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

R. Redfield, C. Fichtenbaum, M. Saag, 2008, The Journal of infectious diseases.

Prevalence of undiagnosed acute and chronic HIV in a lower-prevalence urban emergency department.

M. Lyons, C. Lindsell, C. Fichtenbaum, 2014, American journal of public health.

PrevalenceofUndiagnosedAcuteandChronicHIV inaLower-PrevalenceUrbanEmergencyDepartment

M. Lyons, C. Lindsell, C. Fichtenbaum, 2014 .

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bearing the Burden of Non-AIDS Comorbidities: This Is What Women Aging With Human Immunodefiency Virus Look Like

C. Fichtenbaum, 2020 .

Pro-Inflammatory Alterations of Circulating Monocytes in Latent Tuberculosis Infection

C. Fichtenbaum, Sandra Andorf, C. D. De Cecco, 2022, Open forum infectious diseases.

Endovascular Therapy for Patients With Acute Ischemic Stroke During the COVID-19 Pandemic: A Proposed Algorithm

J. Broderick, C. Fichtenbaum, W. Knight, 2020, Stroke.

Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2022, AIDS.

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

C. Fichtenbaum, N. Stambler, M. Saag, 2010, Antimicrobial Agents and Chemotherapy.

Randomized Comparison of Universal and Targeted HIV Screening in the Emergency Department

M. Lyons, C. Lindsell, C. Fichtenbaum, 2013, Journal of acquired immune deficiency syndromes.

Internal Medicine and Emergency Medicine Physicians Lack Accurate Knowledge of Current CDC HIV Testing Recommendations and Infrequently Offer HIV Testing

M. Lyons, C. Fichtenbaum, E. King, 2012, Journal of the International Association of Physicians in AIDS Care.

Bearing the Burden of Non-AIDS Comorbidities: This is What Women Aging with HIV Look Like.

C. Fichtenbaum, M. Huaman, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection

C. Fichtenbaum, G. Deepe, M. Huaman, 2016, Pathogens & immunity.

High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.

C. Fichtenbaum, J. Aberg, S. Evans, 2011, AIDS.

Take Your Best Shot: Which SARS-CoV-2 Vaccine Should I Get?

C. Fichtenbaum, M. Eckman, A. Smulian, 2021, MDM policy & practice.

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

A. Rancourt, C. Fichtenbaum, P. Douglas, 2020, HIV research & clinical practice.

Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome.

C. Fichtenbaum, W. C. Dunagan, W. Powderly, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Bone Health in People Living With HIV: The Role of Exercise and Directions for Future Research

C. Fichtenbaum, G. McComsey, A. Webel, 2018, The Journal of the Association of Nurses in AIDS Care : JANAC.

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2021, JAMA network open.

Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested.

M. Lyons, C. Lindsell, C. Fichtenbaum, 2011, Annals of emergency medicine.

The Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus Infection

C. Fichtenbaum, M. H. David, 2001 .

Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care.

C. Fichtenbaum, P. Sax, P. Tebas, 2005, IAPAC monthly.

Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.

N. Shire, C. Fichtenbaum, C. Chougnet, 2011, Viral immunology.

Syphilis: Evaluation by MR Imaging and CT Osteomyelitis of the Skull in Early-Acquired

C. Fichtenbaum, I. Huang, 2007 .

Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.

M. Hughes, A. Randolph, C. Fichtenbaum, 2019, The Lancet. Respiratory medicine.

Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK Study.

S. Trottier, C. Fichtenbaum, C. Katlama, 2020, Journal of the American College of Cardiology.

Web-Based Data Collection for Older Adults Living With HIV in a Clinical Research Setting: Pilot Observational Study

C. Fichtenbaum, S. Koletar, C. Roberts-Toler, 2020, Journal of medical Internet research.

Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function

C. Fichtenbaum, P. Sax, D. Haas, 2023, Journal of acquired immune deficiency syndromes.

W. K. Henry, K. Tashima, C. Fichtenbaum, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Web-Based Data Collection for Older Adults Living With HIV in a Clinical Research Setting: Pilot Observational Study (Preprint)

C. Fichtenbaum, S. Koletar, C. Roberts-Toler, 2020 .

Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.

C. Fichtenbaum, M. Smith, 1992, Clinical Infectious Diseases.

Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

Daniel L. Popkin, M. Lederman, C. Fichtenbaum, 2018, Vaccine.

Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea

A. LaMarca, C. Fichtenbaum, D. Asmuth, 2017, HIV clinical trials.

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2023, The New England journal of medicine.

Eosinophilic granuloma of the lung presenting as a solitary pulmonary nodule.

C. Fichtenbaum, G. Kleinman, R. Haddad, 1990, Thorax.

Disparities in Care for HIV Patients

Frank H. Galvan, C. Sherbourne, A. Wu, 2006 .

Emerging reverse transcriptase inhibitors for HIV-1 infection

C. Fichtenbaum, M. A. Rai, Sam Pannek, 2018, Expert opinion on emerging drugs.

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV

C. Fichtenbaum, T. Burdo, T. Mayrhofer, 2024, JAMA cardiology.

Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.

C. Fichtenbaum, G. McComsey, Babafemi O Taiwo, 2018, AIDS.

Short-Term Effect of HAART on Blood Pressure in HIV-Infected Individuals

C. Fichtenbaum, Jodi M. Grandominico, 2008, HIV clinical trials.

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data.

C. Fichtenbaum, J. Aberg, S. Grinspoon, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV

C. Fichtenbaum, T. Burdo, H. Ribaudo, 2024, Journal of acquired immune deficiency syndromes.